New insider activity at Arrowhead Pharmaceuticals ( (ARWR) ) has taken place on December 19, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CEO Christopher Richard Anzalone recently executed a notable stock transaction involving Arrowhead Pharmaceuticals, selling 85,000 shares of the company’s stock. This sale amounted to a total value of $5,443,462, highlighting a multi-million dollar move by the firm’s top executive and drawing attention from investors tracking insider activity at Arrowhead Pharmaceuticals.
Recent Updates on ARWR stock
Over the last day, Arrowhead Pharmaceuticals’ stock has traded against a backdrop of very strong fundamental news and heightened expectations. The company reported a dramatic revenue surge driven by large collaboration and milestone payments (notably from Novartis and Sarepta), which turned a prior large annual loss into near-breakeven results and improved its cash runway. At the same time, the FDA’s approval of its first commercial product, REDEMPLO/Rodemplo, validated its TRiM RNAi platform and supported a more optimistic long‑term growth outlook, particularly given a broad late‑stage and CNS pipeline and plans for multiple data readouts and potential launches in 2026. These positives are tempered by execution and regulatory risks that factor into analysts’ valuation work: program delays in obesity candidates, uncertainty around obtaining a pancreatitis risk‑reduction label expansion for Rodemplo, and the disclosed risk that future generic versions of REDEMPLO or other drugs could erode pricing power and cash flows if exclusivity protections prove weaker than expected. Options activity also indicates the market is pricing in an unusually large post‑earnings move, reflecting the combination of transformative approval, outsized collaboration revenue, and these pipeline and regulatory uncertainties, all of which are key drivers behind recent adjustments to analysts’ price targets rather than simple short‑term trading dynamics.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
Arrowhead Pharmaceuticals’ overall stock score is driven by strong technical momentum and positive developments in its clinical pipeline and partnerships. However, significant financial challenges and valuation concerns weigh heavily on the score. The earnings call provided a cautiously optimistic outlook, but the company’s financial performance remains a critical area for improvement.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
YTD Price Performance: 238.27%
Average Trading Volume: 2,404,569
Technical Sentiment Signal: Buy
Current Market Cap: $8.8B